Nonetheless, the opportunity to assess both astrogliosis and tau pathology by a single in vivo examination has several major advantages as proven by the current data: First, neuropathological features of both tauopathies (astrogliosis and tau) and α-synucleinopathies (astrogliosis) can be assessed by a positive contrast. The gene discussed is MAPT; the disease is tauopathy.